Ziarco Group, a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, has named Pablo Jimenez as chief medical officer. Dr. Jimenez will oversee the clinical development of Ziarco’s programs targeting conditions such as atopic dermatitis and psoriasis. “Dr. Jimenez has an impressive track record as both a physician and a senior pharmaceutical executive,” said Mike Yeadon, president and chief executive officer of Ziarco. “His clinical development and regulatory affai...